Translocation, deletion/amplification, and expression of HMGIC and MDM2 in a carcinoma ex pleomorphic adenoma

American Journal of Pathology

Volumn 160, Issue 2, 2002, Pages 433-440

  Röijer, Eva ^a   Nordkvist, Anders ^a   Ström, Anna Karin ^a   Ryd, Walter ^a   Behrendt, Margareta ^a   Bullerdiek, Jörn ^b   Mark, Joachim ^a   Stenman, Göran ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF BREMEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HIGH MOBILITY GROUP PROTEIN; PROTEIN HMGIC; PROTEIN MDM2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARCINOMA; CARCINOMA EX PLEOMORPHIC ADENOMA; CHROMOSOME 12Q; CONTROLLED STUDY; DOUBLE MINUTE CHROMOSOME; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; KARYOTYPE; MALIGNANT TRANSFORMATION; NUCLEOTIDE SEQUENCE; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; SOUTHERN BLOTTING;

EID: 0036173715     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64862-6     Document Type: Article

References (49)

1. Mixed tumor (pleomorphic adenoma and myoepithelioma)
2. Malignancy in pleomorphic adenoma: A clinical and microspectrophotometric study
3. Cytogenetic investigations on a cell line derived from a carcinoma arising in a salivary gland pleomorphic adenoma
4. Mucoepidermoid tumor of the parotid gland showing a translocation (3;8)(p21;q12) and a deletion (5)(q22) as sole chromosome abnormalities
5. Karyotypic variability and evolutionary characteristics of a polymorphous low grade adenocarcinoma in the parotid gland
6. Chromosome abnormalities in a carcinoma in pleomorphic adenoma of the lacrimal gland
7. Cytogenetical observations in two cases of polymorphous low-grade adenocarcinoma of the salivary glands
8. Cytogenetic findings in seven lacrimal gland neoplasms
9. Characteristic karyotypic features in lacrimal and salivary gland carcinomas
10. Cytogenetic analysis of salivary gland type tumors
11. Malignant salivary gland neoplasms: A cytogenetic study of 19 cases
12. Nonsyntenic amplification of MYC with CDK4 and MDM2 in a malignant mixed tumor of salivary gland
13. Characterization of chromosome aberrations in salivary gland tumors by FISH, including multicolor COBRA-FISH
14. Cytogenetic and molecular observations in human and experimental salivary gland tumors
15. Cytogenetic subtyping of 220 salivary gland pleomorphic adenomas: Correlation to occurrence, histological subtype, and in vitro cellular behavior
16. Impact of the in vitro technique used on the cytogenetic patterns in pleomorphic adenomas
17. Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleomorphic adenomas with t(3;8)(p21;q12) translocations
18. The recurrent translocation t(5;8)(p13;q12) in pleomorphic adenomas resuits in up-regulation of PLAG1 gene expression under control of the LIFR promoter
19. Conserved mechanism of PLAG1 activation in salivary gland tumors with and without chromosome 8q12 abnormalities: Identification of SII as a new fusion partner gene
20. Recurrent rearrangements in the high mobility group protein gene HMGI-C in benign mesenchymal tumours
21. Expression of reciprocal hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma of the parotid gland
22. Identification of NF1B as recurrent translocation partner gene of HMGIC in pleomorphic adenomas
23. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains
24. Architectural transcription factors
25. The AT-DNA-binding domain of mammalian high mobility group I chromosomal proteins: A novel peptide motif for recognizing DNA structure
26. Description of a novel fusion transcript between HMGI-C, a gene encoding for a member of the high mobility group proteins, and the mitochondrial aldehyde dehydrogenase gene
27. LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family
28. LHFP, a novel translocation partner gene of HMGIC in a lipoma, is a member of a new family of LHFP-like genes
29. Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas
30. Novel gene fusion of COX6C at 8q22-23 to HMGIC at 12q15 in a uterine leiomyoma
31. Fusion of a sequence from HEI10 (14q11) to the HMGIC gene at 12q15 in a uterine leiomyoma
32. Non-random chromosome rearrangements in adenoid cystic carcinoma of the salivary glands
33. Identification of a yeast artificial chromosome spanning the 8q12 translocation breakpoint in pleomorphic adenomas with t(3;8)(p21;q12)
34. 2-terminal domain of the basic helix-loop-helix protein TCF12 to TEC in extraskeletal myxoid chondrosarcoma with translocation t(9;15)(q22;q21)
35. Expression and mutation patterns of p53 in benign and malignant salivary gland tumors
36. The transcriptional role of PML and the nuclear body
37. Translocation breakpoints upstream of the HMGIC gene in uterine leiomyomata suggest dysregulation of this gene by a mechanism different from that in lipomas
38. FISH mapping of breakpoints in pleomorphic adenomas with 8q12-13 abnormalities identifies a subgroup of tumors without PLAG1 involvement
39. Recent progress in understanding mechanisms of mammalian DNA amplification
40. Double minute chromosomes can be produced from precursors derived from a chromosomal deletion
41. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas
42. HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas
43. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets
44. On double-minutes and their origin in a benign human neoplasm, a mixed salivary gland tumour
45. Expression and cDNA cloning of human HMGI-C phosphoprotein
46. The expression of the high mobility group HMGI(Y) proteins correlates with the malignant phenotype of human thyroid neoplasias
47. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation